Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2025-05-13 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
民生证券股份有限公司关于杭州安旭生物科技股份有限公司首次公开发行股票并在科创板上市之保荐总结报告书
Regulatory Filings
2025-05-13 Chinese
安旭生物关于召开2024年度暨2025年第一季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling of an investor presentation meeting (业绩说明会) for discussing the 2024 annual and 2025 first quarter financial results. It provides details on the date, time, location, and participation method for the meeting, but does not contain the actual financial data or detailed report itself. The document length is short (1535 characters) and it references that the annual and quarterly reports have already been published. This fits the profile of an Investor Presentation (IP) announcement rather than the full report or earnings release. Therefore, the correct classification is Investor Presentation (IP).
2025-05-12 Chinese
杭州安旭生物科技股份有限公司市值管理制度
Governance Information Classification · 95% confidence The document is titled '市值管理制度' (Market Value Management System) issued by the company's board. It outlines the principles, organizational structure, responsibilities, and procedures for managing the company's market value, including compliance, monitoring, investor relations, share repurchase, and other strategic measures. It is a governance-related internal policy document rather than a financial report, announcement, or regulatory filing. It does not contain financial statements, audit information, earnings data, or voting results. It is not a presentation or a call transcript. The document is a detailed governance framework related to market value management, which fits best under Governance Information (CGR). The document length is 4011 characters, which is substantive and not a brief announcement or certification. Therefore, the classification is CGR with high confidence.
2025-04-29 Chinese
安旭生物关于作废2024年限制性股票激励计划部分限制性股票的公告
Remuneration Information Classification · 95% confidence The document is an official announcement from Hangzhou Anxu Biotechnology Co., Ltd. regarding the cancellation of part of the 2024 restricted stock incentive plan. It details board and supervisory meetings, approvals, legal and financial advisor opinions, and the specific stock incentive plan adjustments. The content focuses on corporate governance and compensation-related decisions about stock incentives, not on financial results, earnings, or annual reports. It is not a full report but a formal announcement of a board decision related to management compensation and stock incentives. This fits best under the category of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors, including stock incentive plans and related changes.
2025-04-29 Chinese
上海锦天城（杭州）律师事务所关于杭州安旭生物科技股份有限公司2024年限制性股票激励计划部分限制性股票作废事项的法律意见书
Regulatory Filings
2025-04-29 Chinese
中审众环会计师事务所（特殊普通合伙）关于安旭生物募集资金年度存放与使用情况的鉴证报告
Regulatory Filings
2025-04-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.